Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Monday. The firm set a “hold” rating on the stock.

Several other equities analysts also recently issued reports on ONCT. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Northland Securities restated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $0.53 on Monday. The stock has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $3.13. Oncternal Therapeutics has a 1-year low of $0.53 and a 1-year high of $13.14. The company has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.